Lista de obras -

Acute Myeloid Leukemia Secondary to Oxaliplatin Treatment for Esophageal Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2011

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

artículo científico publicado en 2012

Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population ⬇️

artículo científico publicado el 26 de abril de 2011

Clinical and functional significance of circular RNAs in cytogenetically normal AML

scientific article published on 01 January 2020

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

artículo científico publicado en 2012

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

artículo científico publicado en 2020

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically

artículo científico publicado en 2019

Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia ⬇️

artículo científico publicado el 6 de septiembre de 2011

Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia ⬇️

artículo científico publicado el 3 de abril de 2013

Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study

artículo científico publicado en 2020

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia

artículo científico publicado en 2019

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA

artículo científico publicado en 2018

Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse ⬇️

artículo científico publicado el 15 de octubre de 2010

Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia ⬇️

artículo científico publicado el 21 de diciembre de 2010

Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells ⬇️

artículo científico publicado el 12 de octubre de 2010

Interpretation of cytogenetic and molecular results in patients treated for CML ⬇️

artículo científico publicado el 17 de marzo de 2011

Is obesity a prognostic factor for acute myeloid leukemia outcome? ⬇️

artículo científico publicado el 21 de septiembre de 2011

Long-term response of refractory primary cold agglutinin disease to eculizumab therapy ⬇️

artículo científico publicado el 31 de mayo de 2013

Modulation of Chemotherapeutic Efficacy by Vascular Disrupting Agents: Optimizing the Sequence and Schedule ⬇️

artículo científico publicado el 30 de enero de 2012

Molecular Epidemiology and Risk Factors for Colonization by Vancomycin-ResistantEnterococcusin Patients with Hematologic Malignancies ⬇️

artículo científico publicado el 1 de mayo de 2011

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

artículo científico publicado en 2018

Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature ⬇️

artículo científico publicado el 18 de mayo de 2013

Myeloid blastic transformation of myeloproliferative neoplasms—A review of 112 cases ⬇️

artículo científico publicado el 19 de agosto de 2010

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome

Phase 1 study of arsenic trioxide, high‐dose cytarabine, and idarubicin to down‐regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia ⬇️

artículo científico publicado el 31 de marzo de 2011

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia ⬇️

artículo científico publicado el 1 de marzo de 2012

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

artículo científico publicado en 2010

Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2013

Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia

artículo científico publicado en 2019

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

artículo científico

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia

artículo científico publicado en 2017

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

artículo científico publicado en 2018

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

scholarly article published 26 December 2018

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

artículo científico publicado en 2011

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

artículo científico publicado en 2020

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2 ⬇️

artículo científico publicado el 1 de enero de 1993

Smoking adversely affects survival in acute myeloid leukemia patients ⬇️

artículo científico publicado el 2 de agosto de 2011

Lista de obras de

Acute Myeloid Leukemia Secondary to Oxaliplatin Treatment for Esophageal Cancer ⬇️

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population ⬇️

Clinical and functional significance of circular RNAs in cytogenetically normal AML

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically

Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia ⬇️

Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia ⬇️

Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA

Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse ⬇️

Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia ⬇️

Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells ⬇️

Interpretation of cytogenetic and molecular results in patients treated for CML ⬇️

Is obesity a prognostic factor for acute myeloid leukemia outcome? ⬇️

Long-term response of refractory primary cold agglutinin disease to eculizumab therapy ⬇️

Modulation of Chemotherapeutic Efficacy by Vascular Disrupting Agents: Optimizing the Sequence and Schedule ⬇️

Molecular Epidemiology and Risk Factors for Colonization by Vancomycin-ResistantEnterococcusin Patients with Hematologic Malignancies ⬇️

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature ⬇️

Myeloid blastic transformation of myeloproliferative neoplasms—A review of 112 cases ⬇️

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome

Phase 1 study of arsenic trioxide, high‐dose cytarabine, and idarubicin to down‐regulate constitutive signal transducer and activator of transcription 3 activity in patients aged &lt;60 years with acute myeloid leukemia ⬇️

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia ⬇️

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia

Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2 ⬇️

Smoking adversely affects survival in acute myeloid leukemia patients ⬇️

Phase 1 study of arsenic trioxide, high‐dose cytarabine, and idarubicin to down‐regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia ⬇️